Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

TransMID phase III program agreed under SPA

May 13, 2004

SPA for phase III GVAX prostate cancer vaccine trial

May 12, 2004

Novel human anticancer vaccine elicits cellular responses

May 12, 2004

Australian Pentrys phase II trial commences

May 5, 2004

Phase II TroVax trial cleared to commence for metastatic renal cancer

May 3, 2004

Positive data for HuMax-CD4 in phase II CTCL studies

April 30, 2004

Esteve takes marketing rights to Wilex's Rencarex in Southern Europe

April 30, 2004

Phase III results of R-1549 in ovarian cancer disappoint

April 28, 2004

Aastrom receives grant to develop immunotherapy for malignant melanoma

April 27, 2004

Phase II trial studies Xcellerated T Cells for multiple myeloma

April 20, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...